Warner Chilcott to develop Dong-A's ED drug in USA
The USA's Warner Chilcott has signed an agreement with Dong-A PharmTech, based in South Korea, to develop and market its orally-administered udenafil product, a phosphodiesterase type 5 inhibitor for erectile dysfunction, in the USA, where Dong-A has successfully completed Phase II studies.
Under the terms of the deal, Warner Chilcott has exclusive US rights to develop and market the product for the treatment of ED. Dong-A will receive an initial, up-front payment and may also be eligible to receive additional amounts upon achievement of certain milestones. Further financial terms were not disclosed.
The product was approved by the Korean Food and Drug Administration in December of 2005 for the treatment of ED in Korea under the brand name Zydena, as well as in Russia in July 2008.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze